To Investigate the Pharmacokinetics, Safety, Tolerability and Efficacy of SHR-2524 Combined With Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) in an Open-label, Multicenter Phase I Clinical Trial
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.
• ≥ 18 years old;
• Advanced hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or clinical diagnosis;
• The Barcelona clinical liver cancer stage was B or C;
• Has not previously received systemic antitumor therapy for HCC;
• At least one measurable lesion according to RECIST v1.1 criteria;
• Child-Pugh score of A or B7 ;
• ECOG score 0 -1;
• The expected survival time was ≥12 weeks;
• The major organs functioned well;
⁃ Has signed the informed consent form.